 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/917
Strategic Perspectives 2001: Narcolepsy - Specific Drugs are Waking up the Market
|
Description: |
Whilst narcolepsy is not a prevalent disorder, the recentsuccess of the first narcolepsy specific drug, Provigil(modafinil) has created interest in this previously neglectedmarket. With its superior efficacy and safety profilecompared to the previous gold standard treatment, theCNS stimulants, Provigil is expected to continue itssuccess for the foreseeable future.However, Provigil is only effective at treating one of thesymptoms of narcolepsy, excessive daytime sleepiness,and does not treat another commonly experiencedsymptom, cataplexy. Another narcolepsy specific drug,Xyrem (sodium oxybate), which is likely to be availablesoon, seems set to fill this unmet need and become verysuccessful in the future. |
|
Contents: |
DATAMONITOR HEALTHCARE
CONTACT DETAILS
EXECUTIVE SUMMARY
Scope
Datamonitor insight into the narcolepsy market
Provigil has established itself as the leading drug in the narcolepsy market remarkably rapidly. This is due to its proven efficacy in treating daytime sleepiness and its improved side effect profile and reduced abuse potential compared to the older treatments.
Xyrem (sodium oxybate) is expected to achieve similar success to modafinil when it is approved for treating cataplexy related to narcolepsy. Since Xyrem and modafinil will initially be indicated for different symptoms of narcolepsy, they are unlikely to be in direct competition at first.
Despite the strength of Provigil and Xyrem, there are some unmet needs in the treatment of narcolepsy which may provide opportunities for new drugs to enter the market in the future.
Summary
Key metrics
TABLE OF CONTENTS
NARCOLEPSY OVERVIEW
Etiology
Symptomology
Causes
Epidemiology
Prevalence
Diagnosis and treatment rates
Summary
Diagnosis of narcolepsy
Diagnostic criteria
Treatment
Treatment aims
Treatment guidelines
NARCOLEPSY MARKET ANALYSIS
Narcolepsy drug profiles
Provigil (modafinil)
CNS stimulants
Pemoline
Selegiline
Antidepressants
US market
Assumptions and sources
Compliance rates
Cost of treatment
Market breakdown
European market
Assumptions and sources
Compliance rates
Cost of treatment
Market breakdown
Japanese market
Assumptions and sources
Compliance rates
Cost of treatment
Market breakdown
Summary
THE FUTURE DECODED
Introduction
Epidemiology forecasts to 2008
Prevalence
Treated population
Pipeline analysis
Xyrem (sodium oxybate)
CEE 03-310
SWOT analysis
Provigil
Xyrem
CNS stimulants
Antidepressants
Market drivers
US forecasts to 2008
Market in 2004
Market in 2008
Summary
European forecasts to 2008
Market in 2004
Market in 2008
Summary
Japanese forecasts to 2008
Market in 2004
Market in 2008
Summary
Summary
APPENDIX
Datamonitor's Central Nervous System Business Unit
Table of tables
Etiology
Epidemiology
Diagnosis, treatment and compliance
Clinical trial data
R&D research methodology
Introduction
Hypothesis formulation
Hypothesis testing
Data verification and quality control
Pricing data
Introduction
Source prices
Ex-manufacturer, wholesaler and retail prices
Data validation and margin calculation
Quality control
Patent data
|
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/917
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 26/11/2009 13:57:40 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Strategic Perspectives 2001: Narcolepsy - Specific Drugs are Waking up the Market
|
|
Web Address: |
http://www.researchandmarkets.com/reports/917
|
|
Office Code: |
|
OC8HJNMPMSTQQ
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Hard Copy
|
|
€2,122.00 + EUR€ 50.00 Shipping/Handling *
|
|
Electronic
|
|
€2,149.00
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 26/11/2009 13:57:40
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
